Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GlaxoSmithkline: Tough Going

Published 04/29/2021, 01:12 AM
Updated 05/14/2017, 06:45 AM

GlaxoSmithKline (NYSE:GSK) shares reacted positively at first to the release of Q1 results, although doubts subsequently set in, with the shares surrendering much of their early gains.

The company reported a sharp reduction in income due to a tough comparison a year previously, plus the impact of reduced patient visits to their GPs and a muted colds and flu season this year. Underlying sales dropped by 15%, and adjusted earnings were some 33% lower than the previous year.

A Weak Quarter For GlaxoSmithKline

Commenting on the numbers, Steve Clayton, manager of the HL Select UK Income Shares fund, which has a position in GSK said:

"The challenges facing GSK this quarter had been well flagged. A year ago, wholesalers were pulling orders forward to stock up ahead of looming lockdowns. Social distancing has kept colds and flu at bay whilst GPs have concentrated on Covid vaccinations, rather than other treatments."

The reduction in profits has led to a weak quarter for cash generation at GSK, and the company needs to show that they can improve this going forward. Strip out some of the one-off changes to customer behaviour due to Covid-19 and the company has some encouraging underlying progress to talk about. New treatments in respiratory and cancer are growing well and as GPs return to normal operations GSK’s Shingrix vaccine for shingles should return to strong growth.

More importantly perhaps though is what GSK don’t want to talk about; the arrival of activist investor Elliot Management on the GSK share register. Elliot have a reputation for shaking up underperforming businesses and driving strategic change. What they will push for at GSK is yet to be seen, but it’s a safe bet that they see more value taking a course different from that which GSK is currently following.

With major structural change on the cards at GSK, with or without Elliot’s alternative vision, it looks set to be a year of forced evolution at GSK.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.